Articles tagged with Primary Tumors
A new mathematical model predicts the presence of undetectable metastases based on primary tumor size, which is associated with a poorer prognosis. The model accurately reflects clinical study data for several cancer types, highlighting the potential dangers of delays in surgery for smaller tumors.
Researchers from University of Pennsylvania develop a mathematical model to understand the dynamics of cancer growth and spread. The study suggests that mutations leading to metastasis often arise early in tumor history, contrary to previous observations.
Researchers have developed primary pancreatic organoid tumor models using magnetic nanoparticle assembly, enabling high-throughput phenotypic drug screening. These 3D structures allow for the testing of drug-like molecules against patient-derived cancer cells, providing insights into potential patient outcomes.
Researchers developed a novel small molecule PET tracer to noninvasively detect EGFR mutation status in NSCLC patients. The approach showed high accuracy and potential for predicting treatment response and monitoring dynamic changes during therapy.
A new study confirms presence of Fusobacterium in liver metastases of colon cancer patients, correlating with tumor growth and colonization. The bacteria travels with metastatic tumor cells to distant organs, potentially aiding their colonization.
A new study found that analyzing genetic variations in tumor tissues can help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma. The research suggests focusing on metastatic sites to improve outcomes.
A study at The Wistar Institute has discovered a slowly proliferating and highly invasive melanoma cell subpopulation that can leave the primary tumor and colonize distant sites. These cells express higher levels of the protein SerpinE2, which plays a critical role in melanoma invasion.
Lymphatic vessels play a crucial role in both cancer metastasis and immune therapy. Researchers have discovered that VEGF-C levels in the blood before immunotherapy can predict its effectiveness in melanoma patients, with patients showing strong responses to treatment when VEGF-C levels are high.
A study found that only 2% of patients with suspected cancer were diagnosed using tumor markers, while most requests led to no diagnosis. The unnecessary tests cost over £95,000 over a year.
Research funded by NFCR finds two distinct patterns of metastatic spread in human colorectal cancer, where distant metastases originate directly from primary tumors without involving the lymph system. The study provides genetic evidence towards resolving the enigma of lymph node metastases and distant metastases.
Researchers have found that lymph node metastases are not always the source of cancer's spread to other organs, and instead, distant metastases can originate directly from the primary tumor. In most cases (65%), both lymph node and distant metastases originated from the same cell type in the primary tumor, indicating independent origins.
Patients with right-sided primary tumours have a 36% better survival rate after treatment with a combination of first-line chemotherapy and selective internal radiation therapy, compared to chemotherapy alone. This treatment combination was no better than chemotherapy only in patients with left-sided primary tumours.
Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cells to recruit at distant sites, establishing niches for future metastases. Liver-infiltrating MDSCs facilitate tumor cell survival in the new location.
Researchers at Mount Sinai discovered that specific signals in primary tumors induce dormant cancer cells that can evade chemotherapy. These 'dormant' cells are found in hypoxic regions of the tumor and may lead to disease relapse and poor prognosis.
A new study published in JAMA Oncology found that left-sided primary tumor location is associated with a nearly 20 percent reduced risk of death. This difference was independent of many clinical factors like tumor stage and receipt of adjuvant chemotherapy.
Dr. Manel Esteller receives top-funding European grant to develop ncRNA DNA Methylation Kit for Cancer of Unknown Primary treatment. The kit aims to improve clinical management and patient outcomes by providing personalized treatment suggestions.
A study published in JAMA Oncology shows that intrinsic molecular subtyping of breast cancer can predict patient outcomes and guide treatment decisions. The research found that the genomic classification of tumors is a key prognostic factor, outperforming traditional variables such as age and number of metastases.
A prospective economic study published in Annals of Internal Medicine found that computed tomographic angiography and functional diagnostic testing strategies for diagnosing coronary artery disease have similar costs through 3 years of follow-up. The study included 9,649 patients enrolled in a clinical trial between 2010 and 2013.
Researchers have identified a promising approach to treating triple-negative breast cancer (TNBC) by targeting the MYC oncogene. The study found that selective killing of MYC-overexpressing TNBC cells can be achieved through inhibition of cell cycle progression and fatty acid oxidation.
A recent study has shown that combining radiation therapy with an immune system-strengthening compound can increase the immune response against tumors, even those outside the radiation field. This breakthrough could lead to longer treatment durations and reduced side effects, as well as new curative options for patients.
A study of over 20,000 women with stage IV breast cancer found improved survival rates, especially among those who received initial breast surgery. The median survival increased from 20 to 26 months, and age, tumor size, hormone receptor status, and year of diagnosis were associated with prolonged survival.
A new study reveals that brain metastases carry distinct genetic profiles compared to primary tumors, suggesting divergent evolutionary pathways and potential sensitivity to targeted therapy drugs. The research identifies clinically significant mutations in over half of patients' brain metastases.
Researchers used PET/CT with Ga-68 DOTATOC to detect primary tumors in patients with metastatic neuroendocrine cancer. The study found that 28% of patients underwent a major change in cancer management due to the imaging technique.
Researchers found that patients with stage I non-small cell lung cancer (NSCLC) and low tumor metabolic activity have increased overall survival. A diagnostic test using fluorodeoxyglucose positron emission tomography (FDG/PET) can help identify patients who may benefit from post-surgical chemotherapy.
Researchers found that MED15 overexpression is associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors. MED15 may serve as a prognostic marker for HNSCC recurrence and as a therapeutic target in HNSCC patients suffering from recurrences.
A recent study published in JNCI: Journal of the National Cancer Institute found that tumor location in colorectal cancer may influence survival. Patients with left-sided primary tumors had better survival outcomes than those with right-sided tumors, suggesting potential differences in gene expression patterns and cancer biology.
Patients with advanced stage IV colorectal cancer are having fewer surgeries, but still showing improved survival rates due to the advent of more effective chemotherapeutic options and biologic treatments. The median survival rate for these patients has increased from 8.6% in 1988 to 17.8% in 2009.
Researchers developed an assay to analyze poly-G repeat mutations in human cancer samples, revealing evolutionary relationships among tumor sites. The study found that individual patients had varying levels of genetic differences between primary tumors and metastases, suggesting early or late metastatic spread.
Researchers tracked lethal prostate cancer to determine the clonal origin of a patient's deadly disease. Using tissue samples, they identified the primary tumor site of the lethal clone, revealing that it originated from a small, low-grade foci rather than the larger high-grade region.
Researchers found that the signaling protein calcineurin upregulates Ang-2, promoting angiogenesis in lung endothelial cells. This pathway is crucial for metastasis, offering new targets for lung cancer therapy.
Researchers have direct evidence that epithelial-to-mesenchymal transition (EMT) occurs in human ovarian cancer patients, resulting in unique characteristics and resistance to chemotherapy. This finding highlights the need for combination therapy targeting both primary tumors and metastatic cells.
A study by University of Pennsylvania researchers found that the tumor suppressor protein Par-4 plays a crucial role in preventing breast cancer recurrence. Low Par-4 expression is associated with an increased risk of recurrence and poor response to chemotherapy, highlighting potential new therapeutic strategies.
A new study has identified CA9, CD31, CD34 and VEGFR1/2 as potential biomarkers for predicting a good response to sunitinib treatment in patients with metastatic clear cell renal cell carcinoma. Patients with low Fuhrman grade tumors and high CA9 expression exhibited improved progression-free and overall survival.
Researchers evaluated CT scans of patients with localized esophageal cancer before and after chemotherapy to identify changes in tumor texture. Smaller change in skewness following chemotherapy was a significant prognostic factor, with median overall survival increasing from 11.1 months to 36.1 months.
Researchers found that enhanced aggressiveness of recurrent tumors is due to changes in immune response, specifically an increase in regulatory T cells and macrophages protecting tumor cells. Blocking these cells with new drugs could be a promising strategy for patients with recurrent disease.
Women with BRCA1 or BRCA2 mutations are at high risk for developing contralateral breast cancer, and certain subgroups are more susceptible based on age and first tumor status. The study found that carriers have a 17.9% 10-year risk, while non-carriers have a 6.0% risk.
Long-term risks of subsequent primary neoplasms were investigated in childhood cancer survivors, with digestive and genitourinary neoplasms showing the highest absolute excess risks. The study found a 3- to 6-fold increased risk for survivors compared to expected rates.
Researchers found that photodynamic therapy can eliminate tumor-associated lymphatic vessels and in-transit tumor cells, reducing metastasis. This approach could be combined with existing surgical techniques to destroy lymphatic vessels draining from tumors.
A new study from Massachusetts General Hospital finds that circulating tumor cells prepare a hospitable environment for tumor growth by bringing along noncancerous cells, facilitating metastasis. The presence of these supporting cells is crucial for the initial growth and survival of tumors at a new site.
A new study found that many pancreatic tumors are slow-growing, taking nearly 20 years to become lethal after the first genetic perturbations appear. This challenges previous theories and suggests a potential window of opportunity for early diagnosis and treatment.
A phase II study found that stereotactic body radiation therapy (SBRT) effectively eliminated targeted tumors in patients with early-stage inoperable non-small cell lung cancer. The treatment resulted in a 97.6% primary tumor control rate at 3 years, outperforming conventional radiotherapy.
A clinical trial has shown that stereotactic body radiation therapy (SBRT) can eliminate primary tumors in nearly 98% of lung cancer patients. The treatment is fast, convenient and effective, with more than half of patients alive three years after diagnosis.
Stereotactic body radiation therapy (SBRT) shows high rates of primary tumor control and improved survival for patients with inoperable non-small cell lung cancer. The study's findings suggest that SBRT provides more than double the rate of primary tumor control compared to conventional radiotherapy.
A combined chemotherapy regimen of capecitabine and oxaliplatin given before chemoradiotherapy and surgery is well tolerated and shows promising anti-tumour activity in patients with poor-risk rectal cancer. The treatment improves overall survival rates, with 68% of patients progression-free after 3 years.
A study published in the Journal of the National Cancer Institute found women with hormone receptor-negative first tumors have twice the risk of developing a second breast cancer compared to those with HR-positive tumors. The research also identified a five-fold increase in risk of a second hormone-receptor negative breast cancer.
Researchers at Cold Spring Harbor Laboratory have discovered endothelial progenitor cells that regulate tumor growth and transform dormant lung metastases into life-threatening lesions. Targeting these cells may provide a novel approach to treating lung cancer.
Researchers found that approximately 97% of patients who received imatinib after surgery did not experience cancer recurrence, compared to 83% of those who received placebo. Gleevec was well-tolerated by most patients and showed significant benefits in decreasing cancer recurrence.
A simple and inexpensive test identifies tumours with protein IMP3, predicting cancer spread, allowing for targeted treatment. Patients with these tumours are six times more likely to develop metastasis and four times more likely to die after surgery.
A large clinical trial of low-dose isotretinoin in early-stage head and neck cancer patients found no reduction in second primary tumors or improved survival. Current smokers had increased rates of second primary tumors and death, highlighting the importance of smoking cessation.
A study of 4,484 patients with first primary melanomas found that 8.6% had multiple primary melanomas, with a higher risk for those with family history or dysplastic nevi. The estimated cumulative 5-year risk of a second primary tumor was 11.4%, with a significant increase in incidence for the development of third primary melanoma.
Researchers found a genetic 'signature' in some solid tumors that predicts their tendency to spread. This signature is present in early stages of cancer and can be detected at diagnosis, supporting the idea that primary tumors are pre-configured to metastasize.
Researchers at Massachusetts General Hospital identify a new mechanism of breast cancer metastasis involving the growth of lymphatic vessels inside tumors. This discovery could lead to new approaches to treating and preventing cancer metastasis.
A Phase II study demonstrates the efficacy of non-surgical radiologic intervention using heat in treating kidney cancers. Dr. Jonathan Lewin has successfully 'ablated' tumors in six patients with no recurrence, surpassing the normal three- to-six-month recurrence rate.
A genetic program has been identified that constructs the pipeline supplying blood and nutrients to colorectal tumors. This program involves a group of 46 genes known as tumor endothelial markers (TEMs), which are elevated tenfold or more in tumor endothelium.
Researchers at Ohio State University discovered a new mechanism of drug resistance in cancer cells, where growth factors protect tumors from anticancer drugs. They found that inhibiting these growth factors may improve chemotherapy effectiveness and reduce dosage needed.
Researchers conducted a Phase II trial of adenoviral p53 gene transfer with radiation therapy, showing 29% of patients achieved local tumor control and 12 of 15 had no active cancer. The study demonstrated considerable promise for combined treatments, comparing favorably to a control rate of less than 20% in patients treated with radia...
A recent study by UCSF researchers has found a strong genetic link between early stage, non-invasive breast cancer cells and disease recurrences. The study suggests that second tumors are caused by residual cells left over from the primary lesion, highlighting the importance of wide surgical margins to prevent recurrence.
Researchers developed a non-toxic peptide that prevents metastatic prostate cancer from spreading to other organs in laboratory rats. The peptide, PHSRN, was effective even when primary tumors were allowed to grow before treatment began.
Researchers documented the earliest steps of tumor formation in mice and rats, showing that cancer cells can grow new blood vessels when just hundreds are present. The study suggests that angiogenesis inhibitors might be useful at the earliest stages of tumor development to prevent recurrence and spread.
A retrospective study published in Cancer journal shows an inverse correlation between the number of lymph nodes and 5-year survival rates. Patients with 20 or more tumor-free lymph nodes had a 4.33 times greater relative risk of dying from metastatic breast cancer, compared to those with fewer than 20.